Gold prices steady ahead of Fed decision, Trump’s tariff deadline
LONDON - Alliance Pharma (LON:ALAPH) plc has announced the fulfillment of all regulatory conditions required for its acquisition by Aegros Bidco Limited, a move that signals significant progress towards finalizing the deal. The acquisition, first announced on January 10, 2025, is set to be executed via a Court-sanctioned scheme of arrangement.
Following the receipt of foreign direct investment clearances from the French Ministry of the Economy and the German Federal Ministry for Economic Affairs and Climate Action (WA:ACT), all regulatory conditions outlined in the Scheme Document have been met as of today. This development comes after the Scheme Shareholders approved the acquisition at a Court Meeting and a subsequent General Meeting on March 13, 2025.
The acquisition process is still subject to the sanction of the Scheme by the Court at the Sanction Hearing scheduled for May 12, 2025, and the delivery of the Court Order to the Registrar of Companies. If all conditions are satisfied, the effective date of the Scheme is expected to be May 14, 2025.
Eligible Scheme Shareholders have until 6:00 p.m. on May 9, 2025, to elect for the Alternative Offer, which is one business day prior to the Sanction Hearing. Those wishing to receive cash for their shares under the terms of the Final Increased Cash Offer should not submit an election for the Alternative Offer.
Under the final increased cash offer, each Scheme Shareholder will receive 64.75 pence in cash for each share, a figure that is set and will not be increased unless a third-party offer for Alliance emerges or the Panel consents to an increase under exceptional circumstances.
This announcement is based on a press release statement and provides the latest information on the acquisition process, which is of interest to investors and stakeholders of Alliance Pharma plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.